Is Buying Calithera Biosciences Inc (NASDAQ:CALA), Having Lower Short Interest a Winning Strategy?

June 24, 2018 - By Hazel Jackson

Calithera Biosciences, Inc. (NASDAQ:CALA) Logo

Investors sentiment decreased to 0.91 in 2018 Q1. Its down 1.29, from 2.2 in 2017Q4. It worsened, as 16 investors sold Calithera Biosciences, Inc. shares while 29 reduced holdings. 10 funds opened positions while 31 raised stakes. 21.05 million shares or 12.94% less from 24.18 million shares in 2017Q4 were reported.
Fmr Lc holds 0% or 680,710 shares. Renaissance Technologies Ltd Liability stated it has 269,900 shares or 0% of all its holdings. American Century invested 0.01% in Calithera Biosciences, Inc. (NASDAQ:CALA). Iconiq Limited Liability holds 0.02% or 23,222 shares. Voya Invest Limited Liability Corp invested in 0% or 14,186 shares. Rhumbline Advisers holds 27,899 shares or 0% of its portfolio. Ellington Mgmt Gru Limited Liability Corp owns 11,100 shares for 0.01% of their portfolio. California Pub Employees Retirement System owns 0% invested in Calithera Biosciences, Inc. (NASDAQ:CALA) for 14,100 shares. Quantitative Inv Limited Liability Com owns 0% invested in Calithera Biosciences, Inc. (NASDAQ:CALA) for 14,200 shares. Millennium Management Ltd has invested 0.01% in Calithera Biosciences, Inc. (NASDAQ:CALA). Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Inv holds 74,000 shares or 0% of its portfolio. Adage Cap Ptnrs Grp Inc Ltd Liability Corporation has invested 0.01% in Calithera Biosciences, Inc. (NASDAQ:CALA). State Board Of Administration Of Florida Retirement Sys reported 0% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA). Illinois-based Balyasny Asset Management has invested 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). Jennison Associate Ltd Com invested 0% in Calithera Biosciences, Inc. (NASDAQ:CALA).

The stock of Calithera Biosciences Inc (NASDAQ:CALA) registered a decrease of 3.67% in short interest. CALA’s total short interest was 2.15M shares in June as published by FINRA. Its down 3.67% from 2.23 million shares, reported previously. With 495,500 shares average volume, it will take short sellers 4 days to cover their CALA’s short positions. The short interest to Calithera Biosciences Inc’s float is 10.48%.

It closed at $5.3 lastly. It is down 65.69% since June 24, 2017 and is downtrending. It has underperformed by 78.26% the S&P500.

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company has market cap of $189.98 million. The Company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. It currently has negative earnings. The firm has a license agreement with Mars, Inc. to develop and commercialize SymbioscienceÂ’s portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

More recent Calithera Biosciences, Inc. (NASDAQ:CALA) news were published by: Nasdaq.com which released: “Calithera to Present at the Jefferies and JMP Securities Healthcare Conferences in June” on June 06, 2018. Also Benzinga.com published the news titled: “The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines” on June 03, 2018. Nasdaq.com‘s news article titled: “Results from Phase 1 Study of CB-839 in Combination with Capecitabine in Advanced Solid Tumors to be Presented at …” with publication date: June 04, 2018 was also an interesting one.

Calithera Biosciences, Inc. (NASDAQ:CALA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.